Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 29;16(1):222.
doi: 10.1186/s12955-018-1047-z.

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study

Affiliations

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study

Amr Makady et al. Health Qual Life Outcomes. .

Abstract

Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in overall survival amongst innovative products may be difficult to measure in clinical trials, and their use may be associated with increased toxicity profiles. Therefore, HTA agencies increasingly require information on HRQoL for the assessment of such drugs. This study explored the feasibility of social media to assess patient perspectives on HRQoL in melanoma, and whether current cancer- and melanoma-specific HRQoL questionnaires represent these perspectives.

Methods: A survey was distributed on the social media channels of Melanoma Patient Network Europe to assess melanoma patients' perspectives regarding HRQoL. Two researchers independently conducted content analysis to identify key themes, which were subsequently compared to questions from one current cancer-specific and two melanoma-specific HRQoL questionnaires (i.e. EORTC QLQ-C30, EORTC QLQ-MEL38, FACT-M).

Results: In total, 72 patients and 17 carers completed the survey. Patients indicated that family, having a normal life, and enjoying life were the three most important aspects of HRQoL for them. Carers indicated that being capable, having manageable adverse events, and being pain-free were the three most important aspects of HRQoL for patients. Respondents seem to find some questions from HRQoL questionnaires relevant (e.g. 'Have you felt able to carry on with things as normal?') and others less relevant (e.g. 'Have you had swelling near your melanoma site?'). Additionally, wording may differ between patients and HRQoL questionnaires, whereby patients generally use a more positive tone.

Conclusions: Social media may provide a valuable tool in assessing patient perspectives regarding HRQoL. However, differences seem to emerge between patient and carer perspectives. Additionally, patient perspectives did not seem to fully correlate to questions posed in cancer- (i.e. EORTC QLQ-C30) and melanoma-specific (i.e. EORTC QLQ-MEL38, FACT-M) HRQoL questionnaires examined.

Keywords: Health related quality of life; Patient perspectives; Real-world data; Social media.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Key aspects patients find important in QoL

References

    1. Health Technology Assessment International. HTAi Glossary. 2017 [cited Dec 2016]. Available from: http://htaglossary.net/tiki-index.php?page=List+all+terms.
    1. HLPF. High Level Pharmaceutical Forum 2005–2008. Final Conclusions and Recommendations of the High Level Pharmaceutical Forum. 2017 [cited Mar 2015].
    1. Matikas A, Mavroudis D. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncol. 2015;11(6):997–1009. doi: 10.2217/fon.14.287. - DOI - PubMed
    1. Valpione S, Campana LG. Immunotherapy for advanced melanoma: future directions. Immunotherapy. 2016;8(2):199–209. doi: 10.2217/imt.15.111. - DOI - PubMed
    1. Kleijnen S, Lipska I, Alves TL, Meijboom K, Elsada A, Vervölgyi V, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Ann Oncol. 2016;1768–775. - PubMed